HUIZHONG NEWS

China’s water‑based adjuvant bivalent inactivated vaccine against Porcine Circovirus Type 2 and Mycoplasma hyopneumoniae has been officially launched.

On November 6, 2018, a grand launch event was held in Luoyang for the water-adjuvanted bivalent inactivated vaccine against Porcine Circovirus Type 2 and Mycoplasma hyopneumoniae, which took eight years to develop. This vaccine was meticulously researched and developed by Luoyang Huizhong Biotechnology Co., Ltd., leveraging the expertise of the National Engineering Research Center for Veterinary Drugs. Luoyang Huizhong Biotechnology Co., Ltd. is a wholly owned subsidiary of Placor Bioengineering Co., Ltd., a leading domestic innovator in animal health technology. Established in 2011, the company builds on the successful 20-year operation of Luoyang Huizhong Veterinary Medicine and the 10-year track record of Placor Bio.

2018-11-08

The Porcine Circovirus Type 2 Bivalent Vaccine is now available—providing dual protection with a single dose, making pig farming even more hassle-free!

On November 6, 2018, Luoyang Huizhong Biotechnology Co., Ltd. (a wholly owned subsidiary of Placor Bioengineering Co., Ltd.), held a product launch event in Luoyang for its bivalent inactivated vaccine against Porcine Circovirus Type 2 and Mycoplasma hyopneumoniae, which was developed over eight years with the support of the National Engineering Research Center for Veterinary Drugs. The “Bivalent Inactivated Vaccine Against Porcine Circovirus Type 2 and Mycoplasma hyopneumoniae” represents a major scientific and technological achievement attained by Huizhong Biotechnology Co., Ltd. through its commitment to the business philosophy of “upright and prudent management,” its strategic vision of “innovation shapes the future,” and the robust technical platform provided by the National Engineering Research Center for Veterinary Drugs. It possesses…

2018-11-08

Amid sweeping industry transformation, where should we go? Combined vaccines lead the way in scientifically reducing the burden of disease prevention and control—Huizhong Bio’s new formulation launch event.

(Xinmu Net, reported from Luoyang) At present, China’s poultry industry is rapidly advancing toward “large-scale production, standardization, intelligent management, and ecological sustainability.” However, persistent outbreaks of disease, unregulated use of preventive and therapeutic medications, and increasingly complex vaccination protocols remain significant challenges hindering the sector’s rapid development. How to achieve “scientific burden reduction and healthy farming” has become a pressing issue that the industry must address. On July 6, 2017, Luoyang Huizhong Biotechnology Co., Ltd. (hereinafter referred to as Huizhong Biotechnology) convened in Luoyang, Henan, a forum on a new immunization model—“Scientific Burden Reduction, Win-Win Cooperation”—alongside a launch event for its newly developed Flow‑Based Method, inviting industry professionals from across the country.

2017-07-09

Advantages of a Novel Bursa of Fabricius Subunit Vaccine in the Control and Prevention of Infectious Bursal Disease in Chickens

Infectious bursal disease (IBD) is an acute, highly contagious, lymphocytolytic infectious disease of young chickens caused by the infectious bursal disease virus (IBDV), which belongs to the genus Birnavirus within the family Birnaviridae. The viral genome consists of two segments, A and B; segment A encodes four proteins—VP5, VP2, VP4, and VP3—in that order, while segment B encodes the VP1 protein. Among these, VP2 is the major structural protein of IBDV and a key host‑protective antigen. Studies have shown that mutations in the hypervariable region of VP2 are among the critical factors underlying changes in viral antigenicity and virulence. IBDV primarily targets the bursa of Fabricius, leading…

2017-04-25

A spirited debate on the industry, with wings of dreams soaring into the future.

In response to the new landscape shaped by the internet, capital investment, and modern animal husbandry, as well as the current state of development in the veterinary biologics industry, the Biologics Sub‑Forum of the High‑Level Forum on Veterinary Drug Industry Development and Livestock Product Safety held a face-to-face interactive session on the afternoon of the 16th. The session was chaired by Hu Qiyi, Chairman of China Animal Health Products Co., Ltd., and featured presentations by Gu Hong, Director of the Pharmaceutical Administration Division of the Veterinary Bureau of the Ministry of Agriculture; Li Wanmeng, Executive General Manager of Merial China; Sun Jinzhong, General Manager of Placor Bioengineering Co., Ltd.; Xiang Huixing, Chairman of Beijing Zhonglian Kang Biotechnology Co., Ltd.; Sun Hao, Chairman of Beijing Huadu Yupin Poultry Co., Ltd.; Wang Yongsheng, General Manager of Jinyu Baoling Biological Pharmaceutical Co., Ltd.; and Qingdao…

2015-09-23

Industry Leaders “Decipher” the Future Trends of Veterinary Chemical Pharmaceuticals

On the afternoon of September 16, the Chemical Pharmaceuticals and Traditional Chinese Veterinary Medicine Sub‑Forum of the High‑Level Forum on Veterinary Drug Industry Development and Livestock Product Safety was solemnly convened in the VIP Hall on the third floor of the Luoyang Modu Lihao International Hotel. Li Xiangdong, Vice President of the China Veterinary Drug Association, delivered a speech, expressing gratitude for the strong support from the Veterinary Bureau, the National Institute for Food and Drug Control, and the Henan Provincial Bureau, as well as for the enthusiastic participation of the heads of leading veterinary drug companies and all corporate representatives in attendance. He emphasized that the central theme of the conference is “innovation”—namely, innovation in science and technology, management, and economic marketing—and that innovative concepts and ways of thinking are the driving force behind the industry’s development. Xu Shixin, Director of the Safety Evaluation Department at the China Institute of Veterinary Drug Supervision, provided an in-depth analysis of the “antibiotic ban.”

2015-09-23